Connect with us

Legal & Regulation

Congress Requires the DEA to Speed Up Action on Medical Marijuana Research Applications

Denis Mariti



DEA to Take Action on Medical Cannabis Applications
- Ad -

Since 30 members of the House of Representatives penned a letter regarding cannabis research, bodies associated with cannabis prohibition have now been under pressure to approve research applications.

The letter was addressed to both the Department of Justice and the Drug Enforcement Administration. It was calling the two to get moving on the applications for cannabis research. Several Democratic candidates who are expected to run for presidency in the next elections also signed the bipartisan letter.

In the letter, the Attorney General and the Acting DEA administrator are urged to speed the research cannabis’ medical benefits.

The letter explains that the FDA and many states in the USA agree that cannabis has medicinal value. However, cannabis is up to date classified by the federal law as a Schedule 1 drug, hence making the research process long and arduous.

The letter indicates that for one to carry out cannabis research, he/she should at the very least work together with three federal Entities – the FDA, DEA, and the National Institute on Drug Abuse. The FDA is tasked with approving and carrying out a site inspection.

DEA to Take Action on Medical Cannabis Research Applications

The DEA has been dragging their feet when it comes to allowing and promoting cannabis research. The letter notes that the DEA has not acted on at least 26 research applications from farms that intend to grow cannabis for the purposes of research. The letter was written with the intention of stopping these delays. It continues to urge the regulating bodies to do whatever they can to speed up and better the research application process.

What ends the letter is a bunch of questions that the DOJ and the DEA are yet to answer. The lawmakers who drafted the letter want to know about the status of the 26 outstanding cannabis research applications and get answers as to why the applications are yet to be approved.

General Jeff Sessions, the former Attorney General, reportedly blocked a number of applications. However, as Barr spoke to Congress, he promised that change would take place in terms of new growers’ application process.

As of now, what remains is waiting to see the DEA’s next move. Perhaps the greatest irony of this matter is that the application for cannabis cultivation is not intended to benefit customers -these companies just want to be legally allowed to grow the plant specifically for research purposes.

As the winds of change prevail, some people will undoubtedly take time to accept cannabis for medicinal purposes and recreation. There will always be people in support of innovations, and those with stigma on anything that relates to cannabis.

Denis is one of the most experienced researchers for reviews we have with years of experience in writing about CBD products. He will be one of the most viewed authors due to his own thrill in sharing what he is learning about cannabidiol and supplement use. With a goal of providing clarity within the budding CBD oil industry, Denis will be spending much of the year going through a catalogue of cannabis oil companies in the near future.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.